Polycystic Ovary Syndrome (PCOS) Market

Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting about one in ten women of reproductive age. The syndrome is characterized by chronic anovulation, or the inability to conceive owing to a lack of ovulation. In addition, PCOS is also associated with elevated testosterone levels and other hormones, which can lead to problems such as acne, excessive hair growth on the face and body, and difficulty losing weight.

Polycystic ovary syndrome is a condition that affects women of reproductive age. It is a common endocrine disorder that occurs when the body’s hormones are out of balance. PCOS can lead to numerous problems, including infertility.

The polycystic ovary syndrome (PCOS) market is anticipated to grow at a CAGR of **% during 2019–2031. PCOS is a metabolic disorder that affects approximately **% of women of reproductive age and is characterized by features such as elevated levels of testosterone, insulin resistance, and irregular menstrual cycles. The high prevalence rates and rising geriatric population are key factors driving the growth of the PCOS market.

The key players in the PCOS market are focusing on: Allergan plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Mylan N.V., Novartis AG, Pfizer Inc., SANOFI, Teva Pharmaceutical Industries, and others.